 CHARLESTON, S.C., Dec. 07, 2020 GLOBE NEWSWIRE -- Aeterna Zentaris Inc. NASDAQ: AEZS TSX: AEZS, through its wholly-owned subsidiary, Aeterna or the Company, a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive licensing agreement the Agreement with Consilient Health, Ltd. CH or Consilient Health, a privately owned pharmaceutical company focused on commercializing medicines in Europe and Middle East, for the commercialization in Europe and the United Kingdom of macimorelin, Aeternas orally available ghrelin agonist, in any diagnostic application, including the diagnosis of patients with adult growth hormone deficiency AGHD and, subject to receipt of regulatory approval, childhood-onset growth hormone deficiency CGHD. 